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A B S T R A C T
Purpose
Posterior fossa ependymoma comprises two distinct molecular variants termed EPN_PFA and
EPN_PFB that have a distinct biology and natural history. The therapeutic value of cytoreductive
surgery and radiation therapy for posterior fossa ependymoma after accounting for molecular
subgroup is not known.
Methods
Four independent nonoverlapping retrospective cohorts of posterior fossa ependymomas (n = 820)
were profiled using genome-wide methylation arrays. Risk stratification models were designed
based on known clinical and newly described molecular biomarkers identified by multivariable Cox
proportional hazards analyses.
Results
Molecular subgroup is a powerful independent predictor of outcome even when accounting for age
or treatment regimen. Incompletely resected EPN_PFA ependymomas have a dismal prognosis,
with a 5-year progression-free survival ranging from 26.1% to 56.8% across all four cohorts. Al-
though first-line (adjuvant) radiation is clearly beneficial for completely resected EPN_PFA, a sub-
stantial proportion of patients with EPN_PFB can be cured with surgery alone, and patients with
relapsed EPN_PFB can often be treated successfully with delayed external-beam irradiation.
Conclusion
The most impactful biomarker for posterior fossa ependymoma is molecular subgroup affiliation,
independent of other demographic or treatment variables. However, both EPN_PFA and EPN_PFB
still benefit from increased extent of resection, with the survival rates being particularly poor for
subtotally resected EPN_PFA, even with adjuvant radiation therapy. Patients with EPN_PFB who
undergo gross total resection are at lower risk for relapse and should be considered for inclusion in
a randomized clinical trial of observation alone with radiation reserved for those who experience
recurrence.
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INTRODUCTION
Ependymoma is the third most common posterior fossa tumor of
childhood and a major cause of morbidity and mortality in pe-
diatric oncology, occurring across the entire age spectrum.1-16
Current therapy for posterior fossa ependymoma in children is
aggressive surgical resection followed by involved-field radiation,
resulting in 7-year event free-survival of 65%.12,15 Despite the high
mortality rate, trials of cytotoxic chemotherapy have failed to reveal
a clear survival benefit for chemotherapy over surgery and radiation
alone, although definitive pediatric randomized trials of maintenance
chemotherapy are still recruiting through cooperative groups
(ClinicalTrials.gov identifiers: NCT01096368 and NCT02265770).1,5,17
In adults, posterior fossa ependymoma is frequently treated with
surgery alone.18
Numerous publications have suggested that the most powerful
prognostic factor for posterior fossa ependymoma is the extent of
surgical resection or, more appropriately, the amount of residual
tumor after surgery. This has entailed an aggressive surgical approach,
with some oncologists and surgeons tolerating serious neurologic
deficits, including the need for tracheostomies and gastrostomy tubes,
as an inevitable cost in the attempt to achieve tumor-free survival,
including potentially morbid second-look surgery.
Because the majority of ependymomas within the neuroaxis
are histologically similar, historically they had been thought to
compose one disease, but they were subsequently recognized to be
biologically distinct in the supratentorial, posterior fossa, and
spinal compartments of the CNS.19 More recently, integrated
genomic approaches have clearly shown the existence of the fol-
lowing three distinct molecular variants of posterior fossa epen-
dymoma: EPN_PFA, EPN_PFB, and subependymoma. EPN_PFA
occurs primarily in infants and young children, whereas EPN_PFB
occurs primarily in older children and adults.20-23 Subependymomas
are grade 1 tumors with an excellent prognosis restricted to older
adults. Patients with EPN_PFB have an excellent outcome, with
survival rates in excess of 90%, whereas patients with EPN_PFA have
a poor outcome. Curiously, neither EPN_PFA nor EPN_PFB has any
recurrent somatic single nucleotide variants, and both demonstrate
a low rate of mutation across the genome.21 The complete lack of
recurrent somatic single nucleotide variants implies that targeted
therapy using small molecules directed against recurrent mutations
is unlikely to be a successful strategy for patients with posterior fossa
ependymoma. EPN_PFA is characterized by relatively increased
DNA methylation compared with EPN_PFB, and preclinical studies
suggest that epigenetic modulating agents might be beneficial for
patients with EPN_PFA.21
All prior studies of the therapeutic value of cytoreductive
surgery and external-beam radiation done in the premolecular era
have not accounted for subgroup affiliation and might therefore be
confounded by clinical differences in response to therapy between
EPN_PFA and EPN_PFB. In addition to extent of resection and
provision of radiotherapy, age at presentation was a strong pos-
terior fossa ependymoma risk factor in the premolecular era lit-
erature. It is unclear whether younger age is an independent risk
factor or is merely a reflection of the enrichment of patients with
EPN_PFA in younger cohorts. Thus, it is unclear whether older
patients with EPN_PFAwill do well, whereas younger patients with
EPN_PFB will do poorly. Previous studies from our group and
others have suggested that the two posterior fossa ependymoma
subgroups may have disparate responses to therapy.20,21 To de-
termine the true value of extent of resection, radiation therapy, and
age at presentation as biomarkers in the molecular era, we present
the largest retrospective cohort of posterior fossa ependymomas
ever assembled and determine the validity and strength of known
biomarkers after accounting for molecular subgroup.
METHODS
Three hundred five posterior fossa ependymomas were obtained from the
Hospital for Sick Children and from collaborating centers from around the
world through the Global Ependymoma Network of Excellence (GENE)
consortium from 1990 to 2014. Samples were all collected in accordance
with the approval of the Hospital for Sick Children Research Ethics Board
and local institutional research ethics boards. To account for unobserved
variables, three independent nonoverlapping validation cohorts were as-
sembled from the prospective St Jude Children’s Research Hospital
(n = 112, RT1 cohort), the Collaborative Ependymoma Research Network
(n = 121, CERN cohort), and the German Cancer Research Center/
Burdenko Neurosurgical Institute (n = 261, Burdenko cohort). Full details of
the cohorts, sample processing, collection of clinical annotations, and
statistical analysis are found in the Appendix (online only).
RESULTS
Demographics of Posterior Fossa Ependymoma Cohorts
Posterior fossa ependymomas from all four cohorts had mo-
lecular subgroup determined using unsupervised hierarchical clus-
tering of genome-wide methylation arrays, as recently described.23 In
total, we analyzed 820 posterior fossa ependymomas, which were
subsequently found to include 678 EPN_PFAs and 142 EPN_PFBs,
with EPN_PFBs more highly enriched in the CERN and Burdenko
cohorts, as reflected by the median age (Table 1). Demographics and
treatment details of each of the four cohorts are listed in Table 1. Grade
was not included as a variable because a previous reanalysis of several
prospective cohort studies showed the existing WHO histologic
classification to be unreliable as a result of profound intraobserver
variability, confounding its utility in clinical risk stratification.24 The
median age of patients with EPN_PFAwas almost identical across all
four cohorts, with a combined median age of 3 years (Appendix Fig
A1, online only; overall age range, 0 to 77 years; GENE: median, 3.6
years; range, 0 to 72 years; St Jude RT1: median, 2.38 years; range, 0.62
to 22.76 years; CERN:median, 4 years; range, 0 to 67 years; Burdenko:
median, 4 years; range, 0 to 65 years). Children younger than age 5
years almost exclusively had EPN_PFA (three EPN_PFB tumors in
patients, 5 years old); however, 45%of pediatric patients age 10 to 17
years had EPN_PFB tumors. Adults largely had EPN_PFB, although
11% of adults had EPN_PFA tumors. Overall, 236 deaths and 420
progression events were observed, and median follow-up time of the
entire cohort was 6.7 years (95% CI, 6.0 to 7.2 years).
Subgroup Affiliation Is the Most Powerful Prognostic
Marker for Posterior Fossa Ependymoma
To determine the prognostic value of ependymoma subgroups,
we performed a Cox proportional hazards regression model across
www.jco.org © 2016 by American Society of Clinical Oncology 2469
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all four cohorts incorporating age, extent of surgical resection,
adjuvant external-beam irradiation, subgroup, and cohort stratifi-
cation (Table 2, Appendix Tables A1-A3, online only). No significant
predictor-cohort interaction was identified for any of these variables
with the exception of adjuvant radiation, which had a stronger effect
in the GENE cohort; thus, we proceeded to pool all four cohorts in
a multivariable analysis (Appendix Table A4, online only). After
accounting for treatment variables, subgroup affiliation remained
a highly significant predictor of progression-free survival (PFS;
hazard ratio [HR], 2.14; 95% CI, 1.31 to 3.49; P = .002, Table 2;
Appendix Tables A1 and A3 report each cohort individually) and
overall survival (OS; HR, 4.30; 95% CI, 1.88 to 9.87; P , .001;
Table 2; Appendix Tables A1 and A3 report each cohort individually).
Administrative censoring at 10 years did not significantly alter the
multivariable analysis (Appendix Tables A2 and A3). The HR for
subgroup affiliation (HR, 4.30) was the highest of the examined
biomarkers. Extent of resection, adjuvant external-beam irradiation,
andmale sex were also significant independent predictors of PFS and
OS, whereas age at diagnosis and delivery of chemotherapy were not.
We then evaluated the survival of patients with EPN_PFA versus
EPN_PFB in each cohort individually. Across the four cohorts,
EPN_PFA had significantly worse PFS and OS compared with
EPN_PFB (Table 2; Appendix Fig A2, online only; Appendix
Tables A1 and A2).
EPN_PFA Carries a Poor Prognosis Independent of Age
at Diagnosis
In the premolecular era, age was an important prognostic
factor for patients with posterior fossa ependymoma. We assessed
the relative hazard for EPN_PFA and EPN_PFB depending on age
and found that the relative risk of an EPN_PFA tumor is relatively
constant across all age groups with a slight decrease for adults and is
consistently higher than for EPN_PFB across the entire age spectrum
(Appendix Fig A3, online only).We restricted our survival analysis to
patients older than age 10 years, and EPN_PFA remained a signif-
icant predictor of poor outcome for both 10-year PFS (P = .001) and
10-year OS (P , .001; Appendix Fig A4 and Appendix Table A5,
online only). Finally, to determine whether older children with
EPN_PFA have a poor outcome, we stratified age as less than or
greater than 10 years and found no significant difference in either
PFS or OS, confirming that the poor prognosis attributed to
EPN_PFA is not solely a result of the young age of the cohort
(Fig 1). A similar analysis was done for EPN_PFB, where survival
was stratified as greater than or less than 18 years with no significant
difference in survival, further reaffirming that EPN_PFB is
a favorable-risk group independent of age at diagnosis (Fig 1).
As such, we conclude that the poor prognosis of EPN_PFA and
the excellent prognosis of EPN_PFB are independent of age at
diagnosis, confirming the results of the multivariable Cox re-
gression analysis.
Surgical Cytoreduction of EPN_PFA Is Prognostic
Independent of Subgroup
Extent of resection is identified in multiple publications as
the single most important predictor of outcome for patients with
posterior fossa ependymoma. However, poor-prognosis EPN_PFA
tumors are a difficult surgical challenge as a result of their lateral
location and occurrence in small infants who have a small blood
volume, whereas good-prognosis EPN_PFB tumors are compar-
atively straightforward to resect as a result of their midline location
and occurrence in an older age group. We hypothesized that the
Table 1. Demographic and Treatment Characteristics of All Four Cohorts
Characteristic
No. of Patients (%)
GENE (n = 326) St Jude’s RT1 (n = 112) CERN (n = 121) Burdenko (n = 261)
Median age, years (interquartile range) 3.6 (1.87-7.45) 2.38 (1.57-4.99) 4 (2-25.5) 4 (2-8.5)
Male sex 175 (53.6) 61 (54.5) 63 (52.1) 152 (58.2)
GTR 221 (68.9) 92 (82.1) 68 (56.7) 138 (53.3)
Adjuvant first-line radiation 250 (78.6) 112 (100) 72 (59) 196 (75.1)
Adjuvant chemotherapy 138 (44.5) 0 42 (34.7) 164 (62.8)
Disease progression 148 (45.7) 40 (35.7) 72 (59.5) 146 (55.9)
Dead 104 (31.9) 41 (33.9) 28 (25) 63 (24.2)
Subgroup
EPN_PFA 275 (84.4) 104 (92.9) 86 (71.1) 213 (81.6)
EPN_PFB 51 (15.6) 8 (7.1) 35 (28.9) 48 (18.4)
NOTE.Dataweremissing for the following:GTR: GENE, n= 4;CERN, n= 1;Burdenko, n = 2; adjuvant first-line radiation:GENE, n = 8; adjuvant chemotherapy: GENE, n= 16;
disease progression: GENE, n = 2; and sex: Burdenko, n = 16.
Abbreviations: CERN, Collaborative Ependymoma Research Network; GENE, Global Ependymoma Network of Excellence; GTR, gross total resection (, 5 mm residual disease).
Table 2. Multivariable Cox Proportional Hazards Regression Model of
Progression-Free and Overall Survival
Variable Hazard Ratio 95% CI P
Progression-free survival (n = 777)
Age 0.99 0.98 to 1.00 .13
Male 1.25 1.02 to 1.54 .03
Incomplete resection 1.84 1.49 to 2.28 , .001
Adjuvant first-line radiation 0.63 0.49 to 0.79 , .001
Chemotherapy 1.04 0.81 to 1.34 .76
EPN_PFA subgroup 2.14 1.31 to 3.49 .002
Overall survival (n = 778)
Age 0.98 0.96 to 1.00 .12
Male 1.41 1.97 to 1.85 .01
Incomplete resection 2.13 1.60 to 2.82 , .001
Adjuvant first-line radiation 0.52 0.38 to 0.72 , .001
Chemotherapy 0.90 0.65 to 1.26 .54
EPN_PFA subgroup 4.30 1.88 to 9.87 , .001
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previously observed therapeutic value for surgical cytoreduction
was confounded by the poor natural history of EPN_PFA tumors,
which are difficult to resect, compared with the benign natural
history of EPN_PFB tumors, which are less difficult to resect.
To determine the relationship between subgroup and extent of
resection after accounting for molecular subgroup, we compared
PFS and OS in each subgroup individually stratified by extent of
resection. When comparing subtotal resection (STR) versus gross
total resection (GTR) in EPN_PFA, STR was highly predictive of
a dismal PFS and OS (Fig 2 and Appendix Table A6, online only).
In a multivariable Cox proportional hazards model that included
adjuvant chemotherapy and radiation, survival remained dismal
for STR EPN_PFA (Appendix Tables A7 and A8, online only).
Although we observed some variability in the effect of extent of
resection across the four cohorts, we did not observe a statistically
significant difference in or heterogeneity of the effect of extent of
resection in EPN_PFA across cohorts (interaction P = .80 for PFS,
P = .53 for OS). Male sex was a significant independent predictor of
poor outcome across all four cohorts in GTR in a multivariable
analysis restricted to EPN_PFA, although STR is a high-risk group
in both male and female patients (Appendix Fig A5, online only,
and Appendix Table A7). Within EPN_PFA, female patients with
a GTR had a 5-year PFS of 0.652 (95% CI, 0.581 to 0.732), whereas
male patients with a GTR had a 5-year PFS of 0.455 (95% CI, 0.393
to 0.527).
The value of first-line (adjuvant post-surgical) radiotherapy
could only be compared with no radiation in the GENE, CERN,
and Burdenko cohorts, because all patients in the prospective
P = .53
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Fig 1. Survival of EPN_PFA and EPN_PFB stratified by age. (A) Progression-free survival (PFS) and (B) overall survival (OS) of EPN_PFA stratified by age greater than or
less than 10 years. (C) PFS and (D) OS of EPN_PFB stratified by age greater than or less than 18 years. P values determined using log-rank test.
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Fig 2. (A, C, E, and G) Progression-free
survival (PFS) and (B, D, F, and H) overall
survival (OS) of EPN_PFA stratified by extent
of resection across all four cohorts. CERN,
Collaborative Ependymoma Research Net-
work; GENE, Global Ependymoma Network
of Excellence; GTR, gross total resection;
STR, subtotal resection (. 5 mm residual
disease). P values determined using log-
rank test.
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St Jude RT1 cohort received adjuvant postoperative radiation.
Strikingly, survival for STR EPN_PFA was not different between
those who received first-line external-beam radiation and those
who did not in the CERNand Burdenko cohorts (Appendix Fig A6,
online only). In the GENE cohort, there was a statistically sig-
nificant difference by a univariable analysis in patients who did not
receive radiation; however, survival remains poor even in patients
with subtotal resections who received external-beam irradiation.
These data suggest that the benefit of post-surgical first-line
adjuvant external-beam irradiation for patients with EPN_PFA
is limited in the face of a subtotal resection and that these patients
should be prioritized for clinical trials of novel therapy.
Patients With GTR EPN_PFB Have an Excellent
Prognosis
As a result of limited patient numbers, we combined patients
with EPN_PFB from the GENE, St Jude RT1, and CERN cohorts
and demonstrated that STR results in a high risk of relapse (10-year
PFS for GTR, 0.740; 95% CI, 0.550 to 0.859; 10-year PFS for STR,
0.50; 95% CI, 0.271 to 0.692). These findings were confirmed in
a cohort of patients with EPN_PFB treated at the Burdenko In-
stitute (Fig 3). As a result of the similar behavior of the two cohorts
and the relatively small number of patients with EPN_PFB in each
cohort, we combined all patients in our subsequent multivariable
analysis. In a multivariable analysis restricted to EPN_PFB, a similar
P = .4
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Fig 3. Value of adjuvant post-operative first-line external-beam irradiation (XRT) in EPN_PFB. (A) Progression-free survival (PFS) and (B) overall survival (OS) of EPN_PFB
across the Global Ependymoma Network of Excellence, St Jude’s, and Collaborative Ependymoma Research Network cohorts. (C) PFS and (D) OS of EPN_PFB across the
Burdenko cohort. P values determined using log-rank test.
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pattern emerges, where an incomplete resection is an independent
predictor of both PFS and OS (Appendix Tables A9 and A10, online
only). However, OS for patients with GTR EPN_PFB is extremely
favorable, with a 10-year OS of 0.961 (95% CI, 0.753 to 0.994),
compared with patients with STR EPN_PFB, who had a 10-year OS
of 0.667 (95% CI, 0.308 to 0.870; Appendix Fig A7, online only).
Interestingly, the PFS for patients with EPN_PFB who did not
receive external-beam irradiation was 0.451 (95% CI, 0.216 to
0.661); however, the OS was 0.823 (95% CI, 0.519 to 0.943). These
data suggest that a subset of patients with EPN_PFB can be cured by
surgery alone after GTR (Fig 3). Of the three nonirradiated patients
with EPN_PFB who died, two had an STR and one had a GTR. A
substantial portion of patients with EPN_PFB who experience re-
currence after initially withholding radiation can potentially be
successfully treated by repeat surgery and delayed delivery of ra-
diation (Fig 3). Indeed, the effect of a GTR versus an STR in
EPN_PFB was significant for both the three combined cohorts and
for the Burdenko cohort (P = .02 in univariable Cox regression
A
Score
0 1 2 3 4 5 6 7 8 9 10
EOR (subgroup = PFB)
GTR
STR
EOR (subgroup = PFA)
GTR
STR
Age
> 18 > 10−18
< 3 3−10
First-line radiation
yes
yes
no
Chemotherapy
no
Sex
F
M
Score sum
0 2 4 6 8 10 12 14 16 18 20
5-year PFS probability
0.10.20.30.40.50.60.70.8
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0.10.20.30.40.50.60.70.8
Nomogram for Multivariable Cox Model: PFS
B
Score
0 1 2 3 4 5 6 7 8 9 10
EOR (subgroup = PFB)
GTR
STR
EOR (subgroup = PFA)
GTR
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Age
> 18 3−10
< 3 > 10−18
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no
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Fig 4. Nomogram of (A) progression-free survival (PFS) and (B) overall survival (OS) of posterior fossa ependymoma based on the multivariable Cox proportional hazards
model. Each effect is translated into a risk score. The individual risk scores need to be totaled by the reader. The score sum can be translated into predicted 5- and 10-year
PFS and OS probabilities. EOR, extent of resection; F, female; GTR, gross total resection; M, male; STR, subtotal resection.
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analysis). Because the long-term effects of radiation for posterior
fossa ependymoma in young adults who are cured can be quite
severe,25-28 these data provide the necessary clinical equipoise for
initiation of a clinical trial of initial radiation avoidance in patients
with GTR EPN_PFB ependymoma.
DISCUSSION
We have defined the demographic and prognostic properties of the
two subgroups of posterior fossa ependymoma across the largest
cohort of posterior fossa ependymoma assembled to date. Al-
though three of the cohorts consist of retrospective data, the St
Jude RT1 cohort was prospectively followed and homogeneously
treated. The cohort is of such a large size that it will not likely be repeated
in our lifetime, nor is a prospective clinical trial randomly assigning
extent of resection in posterior fossa ependymoma patients likely.
We have shown that although EPN_PFA occurs primarily in
infants and EPN_PFB is diagnosed primarily in adults, in children
age 10 to 17 years, there is equal representation of both subgroups.
Moreover, in adults, approximately 11% of patients have EPN_PFA.
Across the entire age spectrum, we show that subgroup is the most
powerful predictor of outcome, suggesting that in patients older than
age 5 years, there is significant information to be gained in routine
subgrouping of patients with posterior fossa ependymoma. Ex-
tent of resection, although no longer the most powerful predictor
of outcome, remains prognostic in both subgroups. In particular,
patients with STR EPN_PFA constitute a high-risk group with
a poor outcome. Finally, we have shown that a subset of patients
with EPN_PFB can be treated with surgery alone without external-
beam irradiation, suggesting a trial of observation alone may
be warranted in this subset of patients. Overall, in a prediction
model of subgroup, treatment, and extent of resection as depicted
in a nomogram, we find that EPN_PFA is the strongest predictor
of poor outcome (Fig 4). Male sex was also an independent
predictor of poor outcome in our analysis across all four cohorts,
which is consistent with previous reports.12 Interestingly the
survival advantage in females is most pronounced in the setting of
GTR EPN_PFA. Amore comprehensive integrated genomic study
will likely be required to clarify this association; however, it is
noteworthy that females with a GTR have 10-year survival rates
approximately 15% higher than males.
Our finding that patients with STR EPN_PFA have a dismal
outcome has significant implications to the design of future clinical
trials. Although a simple proximate solution would be to suggest
GTR in all patients, this is frequently not possible as a result of
brainstem invasion. Additionally, this subset of EPN_PFA seems to
confer the least benefit from adjuvant external-beam irradiation
and could potentially benefit from novel therapies. Previous studies
of chemotherapy have shown only limited activity against posterior
fossa ependymoma, with high-dose chemotherapy with autolo-
gous stem-cell support resulting in 3-year event-free survival of less
than 30%, consistent with the survival we observed.29,30 The role of
adjuvant chemotherapy will require completion and reporting of
long-term outcomes in the open studies of both the European
Society of Pediatric Oncology (SIOPe) and the Children’s Oncology
Group (ACNS0831), where patients are randomly assigned to
maintenance chemotherapy. Our findings across four independent
cohorts of posterior fossa ependymoma suggest that STR EPN_PFA
should be prioritized for first-line investigational agents, such as
DNA demethylase inhibitors and EZH2 inhibitors, to provide an
opportunity to assess activity of these agents prior to radiation.21
Indeed, even patients with GTR EPN_PFA have OS rates of close
to 50%, suggesting aggressive surgeries are not curative, and novel
approaches would benefit this group as well.
We also find that STR confers a significantly poorer prognosis
in EPN_PFB. Considering that the 10-year OS for EPN_PFB is
greater than 85% with a complete resection, we feel that a GTR
should be attempted where possible. The EPN_PFB data are
limited by small numbers of STR patients and, as such, warrant
some caution in interpretation. Major limitations of our study are
a lack of central review of postoperative imaging in the three
retrospective cohorts, retrospective design of the study without
uniform follow-up imaging to identify progression, and treat-
ment heterogeneity. Indeed, nonenhancing residual tumor can
be missed even with modern postoperative magnetic resonance
imaging. A large prospective radiographic study using modern
three-dimensional magnetic resonance imaging volumetrics with
a receiver operating curve will be needed to determine precisely how
much residual tumor is truly predictive of a poor prognosis.
Finally, our finding that EPN_PFB can potentially be cured
without external-beam irradiation has profound implications.
Across the EPN_PFB cohort, we demonstrate many patients who
have not experienced recurrence despite the lack of radiation
therapy. Therefore, our data suggest that radiation in EPN_PFB can
be initially withheld and that patients who experience recurrence
can potentially be treated with salvage reresection and radiation.
The ability to successfully treat patients with EPN_PFB with repeat
surgery and radiation therapy is demonstrated by the large
difference between PFS and OS in this patient population.
Considering that the majority of adult posterior fossa epen-
dymoma patients are not treated on open protocols, pro-
spective evaluation will be crucial to determine the optimal
treatment approach. We feel that our data support consider-
ation of a prospective clinical trial of observation alone for
GTR EPN_PFB, which could potentially spare patients the
toxic effects of radiation.31 The age group in which this could confer
the highest benefit would be the older pediatric and adolescent
population, in whom radiation has significant effects on learning
and memory, and this approach could significantly improve long-
term quality of life in this subset of patients.
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS
OF INTEREST
Disclosures provided by the authors are available with this article at
www.jco.org.
AUTHOR CONTRIBUTIONS
Conception and design: Vijay Ramaswamy, Stephen C. Mack, Terri S.
Armstrong, Andrey Korshunov, David W. Ellison, Michael D. Taylor
Provision of study materials or patients: All authors
Collection and assembly of data: Vijay Ramaswamy, Stephen C. Mack,
Tong Lin, Kristian W. Pajtler, David T.W. Jones, Betty Luu, Kenneth
Aldape, Marc Remke, Martin Mynarek, Stefan Rutkowski, Sridharan
www.jco.org © 2016 by American Society of Clinical Oncology 2475
Ramaswamy et al
Downloaded from ascopubs.org by 69.119.185.214 on January 3, 2017 from 069.119.185.214
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
Gururangan, Roger E. McLendon, Eric S. Lipp, Christopher Dunham,
Juliette Hukin, David D. Eisenstat, Dorcas Fulton, Frank K.H. van
Landeghem, Mariarita Santi, Marie-Lise C. van Veelen, Erwin G. VanMeir,
Satoru Osuka, Xing Fan, Karin M. Muraszko, Daniela P.C. Tirapelli, Sueli
M. Oba-Shinjo, Suely K.N. Marie, Carlos G. Carlotti, Ji Yeoun Lee, Amulya
A. Nageswara Rao, Caterina Giannini, Claudia C. Faria, Sofia Nunes,
Jaume Mora, Ronald L. Hamilton, Peter Hauser, Nada Jabado, Kevin
Petrecca, Shin Jung, Luca Massimi, Massimo Zollo, Giuseppe Cinalli,
La´szlo´ Bogna´r, Almos Klekner, Tibor Hortoba´gyi, Sarah Leary, Ralph P.
Ermoian, James M. Olson, Jeffrey R. Leonard, Corrine Gardner, Wieslawa
A. Grajkowska, Lola B. Chambless, Jason Cain, Charles G. Eberhart, Sama
Ahsan, Maura Massimino, Felice Giangaspero, Francesca R. Buttarelli,
Roger J. Packer, Lyndsey Emery, William H. Yong, Horacio Soto, Linda M.
Liau, Richard Everson, Andrew Grossbach, Tarek Shalaby, Michael
Grotzer, Matthias A. Karajannis, David Zagzag, Helen Wheeler, Katja von
Hoff, Marta M. Alonso, Teresa Tuñon, Ulrich Schu¨ller, Karel Zitterbart,
Jaroslav Sterba, Jennifer A. Chan, Miguel Guzman, Samer K. Elbabaa,
Howard Colman, Girish Dhall, Paul G. Fisher, Maryam Fouladi, Amar
Gajjar, Stewart Goldman, Eugene Hwang, Marcel Kool, Harshad Ladha,
Elizabeth Vera-Bolanos, Khalida Wani, Frank Lieberman, Tom Mikkelsen,
Antonio M. Omuro, Ian F. Pollack, Michael Prados, H. Ian Robins,
Riccardo Soffietti, Jing Wu, Phillipe Metellus, Uri Tabori, Ute Bartels, Eric
Bouffet, Cynthia E. Hawkins, James T. Rutka, Peter Dirks, StefanM. Pfister,
Thomas E. Merchant, Mark R. Gilbert, Terri S. Armstrong, Andrey
Korshunov, David W. Ellison
Data analysis and interpretation: Vijay Ramaswamy, Thomas Hielscher,
Alvaro Lassaletta, Tong Lin, David T.W. Jones, Betty Luu, Florence M.G.
Cavalli, Kenneth Aldape, Marc Remke, Stefan M. Pfister, Mark R. Gilbert,
Terri S. Armstrong, Andrey Korshunov, David W. Ellison, Michael D.
Taylor
Manuscript writing: All authors
Final approval of manuscript: All authors
REFERENCES
1. Bouffet E, Tabori U, Huang A, et al: Ependy-
moma: Lessons from the past, prospects for the
future. Childs Nerv Syst 25:1383-1384, 2009
2. Raybaud C, Ramaswamy V, Taylor MD, et al:
Posterior fossa tumors in children: Developmental
anatomy and diagnostic imaging. Childs Nerv Syst
31:1661-1676, 2015
3. Thompson YY, Ramaswamy V, Diamandis P,
et al: Posterior fossa ependymoma: Current insights.
Childs Nerv Syst 31:1699-1706, 2015
4. Mack SC, Taylor MD: The genetic and epi-
genetic basis of ependymoma. Childs Nerv Syst 25:
1195-1201, 2009
5. Souweidane MM, Bouffet E, Finlay J: The role
of chemotherapy in newly diagnosed ependymoma
of childhood. Pediatr Neurosurg 28:273-278, 1998
6. Purdy E, Johnston DL, Bartels U, et al:
Ependymoma in children under the age of 3 years:
A report from the Canadian Pediatric Brain Tumour
Consortium. J Neurooncol 117:359-364, 2014
7. Bouffet E, Tabori U, Bartels U: Paediatric
ependymomas: Should we avoid radiotherapy?
Lancet Oncol 8:665-666, 2007
8. Yao Y, Mack SC, Taylor MD: Molecular genetics
of ependymoma. Chin J Cancer 30:669-681, 2011
9. U-King-Im JM, Taylor MD, Raybaud C: Pos-
terior fossa ependymomas: New radiological classi-
fication with surgical correlation. Childs Nerv Syst 26:
1765-1772, 2010
10. Dubuc AM, Northcott PA, Mack S, et al: The
genetics of pediatric brain tumors. Curr Neurol Neurosci
Rep 10:215-223, 2010
11. Koshy M, Rich S, Merchant TE, et al: Post-
operative radiation improves survival in children
younger than 3 years with intracranial ependymoma.
J Neurooncol 105:583-590, 2011
12. Merchant TE, Li C, Xiong X, et al: Conformal
radiotherapy after surgery for paediatric ependy-
moma: A prospective study. Lancet Oncol 10:258-266,
2009
13. Merchant TE, Boop FA, Kun LE, et al: A ret-
rospective study of surgery and reirradiation for re-
current ependymoma. Int J Radiat Oncol Biol Phys
71:87-97, 2008
14. Merchant TE, Fouladi M: Ependymoma: New
therapeutic approaches including radiation and che-
motherapy. J Neurooncol 75:287-299, 2005
15. Merchant TE, Mulhern RK, Krasin MJ, et al:
Preliminary results from a phase II trial of conformal
radiation therapy and evaluation of radiation-related
CNS effects for pediatric patients with localized
ependymoma. J Clin Oncol 22:3156-3162, 2004
16. Merchant TE, Zhu Y, Thompson SJ, et al:
Preliminary results from a phase II trial of conformal
radiation therapy for pediatric patients with localised
low-grade astrocytoma and ependymoma. Int J
Radiat Oncol Biol Phys 52:325-332, 2002
17. DeWireM, Fouladi M, Turner DC, et al: An open-
label, two-stage, phase II study of bevacizumab and
lapatinib in children with recurrent or refractory epen-
dymoma: A Collaborative Ependymoma Research
Network study (CERN). J Neurooncol 123:85-91, 2015
18. Ruda` R, Gilbert M, Soffietti R: Ependymomas
of the adult: Molecular biology and treatment. Curr
Opin Neurol 21:754-761, 2008
19. Taylor MD, Poppleton H, Fuller C, et al: Radial
glia cells are candidate stem cells of ependymoma.
Cancer Cell 8:323-335, 2005
20. Witt H, Mack SC, Ryzhova M, et al: De-
lineation of two clinically and molecularly distinct
subgroups of posterior fossa ependymoma. Cancer
Cell 20:143-157, 2011
21. Mack SC, Witt H, Piro RM, et al: Epigenomic
alterations define lethal CIMP-positive ependymo-
mas of infancy. Nature 506:445-450, 2014
22. Johnson RA, Wright KD, Poppleton H, et al:
Cross-species genomics matches driver mutations
and cell compartments to model ependymoma. Na-
ture 466:632-636, 2010
23. Pajtler KW, Witt H, Sill M, et al: Molecular
classification of ependymal tumors across all CNS
compartments, histopathological grades, and age
groups. Cancer Cell 27:728-743, 2015
24. Ellison DW, Kocak M, Figarella-Branger D,
et al: Histopathological grading of pediatric ependy-
moma: Reproducibility and clinical relevance in Eu-
ropean trial cohorts. J Negat Results Biomed 10:7,
2011
25. Mabbott DJ, Spiegler BJ, Greenberg ML, et al:
Serial evaluation of academic and behavioral out-
come after treatment with cranial radiation in child-
hood. J Clin Oncol 23:2256-2263, 2005
26. Spiegler BJ, Bouffet E, Greenberg ML, et al:
Change in neurocognitive functioning after treatment
with cranial radiation in childhood. J Clin Oncol 22:
706-713, 2004
27. Merchant TE, Pollack IF, Loeffler JS: Brain tu-
mors across the age spectrum: Biology, therapy, and
late effects. Semin Radiat Oncol 20:58-66, 2010
28. Mulhern RK, Merchant TE, Gajjar A, et al: Late
neurocognitive sequelae in survivors of brain tu-
mours in childhood. Lancet Oncol 5:399-408, 2004
29. Venkatramani R, Ji L, Lasky J, et al: Outcome
of infants and young children with newly diagnosed
ependymoma treated on the “Head Start” III
prospective clinical trial. J Neurooncol 113:285-291,
2013
30. Bouffet E, Foreman N: Chemotherapy for in-
tracranial ependymomas. Childs Nerv Syst 15:563-570,
1999
31. Lassaletta A, Bouffet E, Mabbott D, et al:
Functional and neuropsychological late outcomes in
posterior fossa tumors in children. Childs Nerv Syst
31:1877-1890, 2015
Affiliations
Vijay Ramaswamy, Stephen C. Mack, Alvaro Lassaletta, Betty Luu, Florence M.G. Cavalli, Uri Tabori, Ute Bartels, Eric Bouffet,
Cynthia E. Hawkins, James T. Rutka, Peter Dirks, and Michael D. Taylor, The Hospital for Sick Children; Vijay Ramaswamy, Kenneth
Aldape, James T. Rutka, and Michael D. Taylor, University of Toronto; Kenneth Aldape, Princess Margaret Cancer Centre, University
Health Network, Toronto, Ontario; Christopher Dunham and Juliette Hukin, British Columbia Children’s Hospital; Juliette Hukin,
University of British Columbia, Vancouver, British Columbia; David D. Eisenstat, Dorcas Fulton, and Frank K.H. van Landeghem,
University of Alberta, Edmonton; Jennifer A. Chan, University of Calgary, Calgary, Alberta; Nada Jabado and Kevin Petrecca, McGill
University, Montreal, Quebec, Canada; Thomas Hielscher, Kristian W. Pajtler, David T.W. Jones, Marcel Kool, Stefan M. Pfister, and
Andrey Korshunov, German Cancer Research Center; Stefan M. Pfister, University Hospital Heidelberg, Heidelberg; Marc Remke,
University Hospital Du¨sseldorf, Du¨sseldorf; Martin Mynarek, Stefan Rutkowski, and Katja von Hoff, University Medical Center
2476 © 2016 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Treatment of Posterior Fossa Ependymoma Subgroups
Downloaded from ascopubs.org by 69.119.185.214 on January 3, 2017 from 069.119.185.214
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
Hamburg-Eppendorf, Hamburg; Ulrich Schu¨ller, Ludwig-Maximilians-Universita¨t, Munich, Germany; Stephen C. Mack, Cleveland Clinic
Foundation, Cleveland; Maryam Fouladi, University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH; Tong
Lin, Amar Gajjar, Thomas E. Merchant, and David W. Ellison, St Jude Children’s Research Hospital, Memphis; Lola B. Chambless,
Vanderbilt Medical Center, Nashville, TN; Sridharan Gururangan, Roger E. McLendon, and Eric S. Lipp, Duke University, Durham; Jing
Wu, University of North Carolina at Chapel Hill, Chapel Hill, NC; Mariarita Santi, Children’s Hospital of Philadelphia; Lyndsey Emery,
Hospital of the University of Pennsylvania, Philadelphia; Ronald L. Hamilton and Ian F. Pollack, University of Pittsburgh School of
Medicine; Frank Lieberman, University of Pittsburgh Medical Center, Pittsburgh, PA; Erwin G. Van Meir and Satoru Osuka, Emory
University, Atlanta, GA; Xing Fan and Karin M. Muraszko, University of Michigan Medical School, Ann Arbor; Tom Mikkelsen, Henry
Ford Health System, Detroit, MI; Sarah Leary, Ralph P. Ermoian, and James M. Olson, Seattle Children’s Hospital; Sarah Leary, Ralph P.
Ermoian, and James M. Olson, Fred Hutchinson Cancer Research Center; Sarah Leary, Ralph P. Ermoian, and James M. Olson, University
of Washington, Seattle, WA; Jeffrey R. Leonard and Corrine Gardner, Washington University School of Medicine and St Louis Children’s
Hospital; Miguel Guzman and Samer K. Elbabaa, St Louis University School of Medicine, St Louis, MO; Charles G. Eberhart and Sama
Ahsan, John Hopkins University School of Medicine, Baltimore; Mark R. Gilbert, National Cancer Institute, Bethesda, MD; Roger J. Packer
and Eugene Hwang, Children’s National Medical Center, Washington, DC; William H. Yong, Horacio Soto, Linda M. Liau, and Richard
Everson, David Geffen School of Medicine at University of California, Los Angeles; Girish Dhall, Children’s Hospital Los Angeles, Los
Angeles; Paul G. Fisher, Stanford University Medical Center, Stanford; Michael Prados, University of California San Francisco, San
Francisco, CA; Andrew Grossbach, University of Iowa Hospitals and Clinics, Iowa City, IA; Matthias A. Karajannis and David Zagzag, New
York University Langone Medical Center; Antonio M. Omuro, Memorial Sloan-Kettering Cancer Center, New York, NY; Howard Colman,
Huntsman Cancer Institute, University of Utah Health System, Salt Lake City, UT; Amulya A. Nageswara Rao and Caterina Giannini, Mayo
Clinic, Rochester, MN; Stewart Goldman, Lurie Children’s Hospital, Chicago, IL; Harshad Ladha, Elizabeth Vera-Bolanos, Khalida Wani,
and Mark R. Gilbert, The University of Texas MDAnderson Cancer Center; Terri S. Armstrong, University of Texas Health Science Center,
Houston, TX; H. Ian Robins, University of Wisconsin, Madison, WI; Marie-Lise C. van Veelen, Erasmus University Medical Center,
Rotterdam, the Netherlands; Daniela P.C. Tirapelli, Sueli M. Oba-Shinjo, Suely K.N. Marie, and Carlos G. Carlotti, University of Sao Paulo,
São Paulo, Brazil; Ji Yeoun Lee, Seoul National University College of Medicine, Seoul; Shin Jung, Chonnam National University Research
Institute of Medical Sciences, ChonnamNational University Hwasun Hospital andMedical School, Hwasun-gun, Chonnam, South Korea;
Claudia C. Faria, Centro Hospitalar Lisboa Norte, Hospital de Santa Maria; Sofia Nunes, Instituto Portugueˆs de Oncologia de Lisboa
Francisco Gentil, Lisbon, Portugal; Jaume Mora, Hospital Sant Joan de De´u, Esplugues de Llobregat, Barcelona; Marta M. Alonso,
University Hospital of Navarra, Pamplona; Teresa Tuñon, Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain; Peter Hauser,
Semmelweis University, Budapest; La´szlo´ Bogna´r, Almos Klekner, and Tibor Hortoba´gyi, University of Debrecen, Debrecen, Hungary;
Luca Massimi, Catholic University Medical School; Francesca R. Buttarelli, Sapienza University of Rome, Rome; Massimo Zollo and
Giuseppe Cinalli, University of Naples; Giuseppe Cinalli, Ospedale Santobono-Pausilipon, Naples; Maura Massimino, Fondazione Istituto
di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale dei Tumori, Milan; Felice Giangaspero, Sapienza University of
Rome–Policlinico Umberto I and IRCCS Neuromed, Pozzilli; Riccardo Soffietti, University of Turin, Turin, Italy; Wieslawa A. Grajkowska,
The Children’s Memorial Health Institute, Warsaw, Poland; Jason Cain, The Hudson Institute of Medical Research, Clayton, Victoria;
Helen Wheeler, Kolling Institute of Medical Research, The University of Sydney, Sydney, New South Wales, Australia; Tarek Shalaby and
Michael Grotzer, University Children’s Hospital of Zurich, Zurich, Switzerland; Karel Zitterbart and Jaroslav Sterba, Masaryk University,
Brno, Czech Republic; and Phillipe Metellus, Centre Hospitalier Clairval, Marseille, France.
Support
M.D.T. is supported by funds from the Garron Family Chair in Childhood Cancer Research at the Hospital for Sick Children and the
University of Toronto and operating funds from the Pediatric Brain Tumor Foundation, Meagan’sWalk, the Rally Foundation, the National
Institutes of Health (NIH; Grants No. R01CA159859 and R01CA148699), and the Canadian Institutes of Health Research (CIHR). V.R. is
supported by a CIHR fellowship, an Alberta Innovates-Health Solutions Clinical Fellowship, a Collaborative Ependymoma Research
Network (CERN) Foundation fellowship, and an Alex’s Lemonade Stand Young Investigator Award. E.B. and V.R. acknowledge support
from b.r.a.i.n.child. S.G., R.E.M., and D.B. are supported by the Pediatric Brain Tumor Foundation. M.R. is supported by a fellowship from
the Mildred Scheel Cancer Foundation. S.M.P. is supported by a grant from the Deutsche Kinderkrebsstiftung. M.A.K. and D.Z. are
supported by the NYU Langone Human Specimen Resource Center, Laura and Isaac Perlmutter Cancer Center, and Clinical and
Translational Science Institute (CTSI), which were partially supported by the Cancer Center Support Grant P30CA016087 and a grant
from the National Center for the Advancement of Translational Science (NCATS) (UL 1 TR000038), NIH, and grants from The Making
Headway Foundation. A.K. was supported by the Hungarian Brain Research Program (Grant No. KTIA_13_NAP-A-V/3), the TA´MOP-
4.2.2.A-11/1/KONV-2012-0025 project, and Ja´nos Bolyai Scholarship of the Hungarian Academy of Sciences. K.Z. acknowledges the
support of an Institutional Research Project grant to junior researchers from the Faculty of Medicine, Masaryk University. E.V.M. is funded
by NIH Grants No. R01 CA163722 and NS096236, St Baldrick’s Foundation, and the Cure Childhood Cancer Foundation. M.D.T., V.R.,
K.A., T.S.A., and M.R.G. are supported by the CERN Foundation.
n n n
www.jco.org © 2016 by American Society of Clinical Oncology 2477
Ramaswamy et al
Downloaded from ascopubs.org by 69.119.185.214 on January 3, 2017 from 069.119.185.214
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective
Multicohort Analysis
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are
self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more
information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or jco.ascopubs.org/site/ifc.
Vijay Ramaswamy
No relationship to disclose
Thomas Hielscher
No relationship to disclose
Stephen C. Mack
No relationship to disclose
Alvaro Lassaletta
Travel, Accommodations, Expenses: Takeda
Tong Lin
No relationship to disclose
Kristian W. Pajtler
No relationship to disclose
David T.W. Jones
No relationship to disclose
Betty Luu
No relationship to disclose
Florence M.G. Cavalli
No relationship to disclose
Kenneth Aldape
Leadership: Celldex, Merck
Marc Remke
No relationship to disclose
Martin Mynarek
Employment: Novartis (I), GlaxoSmithKline (I)
Stefan Rutkowski
Consulting or Advisory Role: Novartis Germany
Sridharan Gururangan
Honoraria: Biomarin
Consulting or Advisory Role: Biomarin
Speakers’ Bureau: Biomarin
Expert Testimony: MMIC Insurance
Roger E. McLendon
Consulting or Advisory Role: Genetron Health Holding
Patents, Royalties, Other Intellectual Property: Poliovirus receptor
detection method–patent applied
Eric S. Lipp
No relationship to disclose
Christopher Dunham
No relationship to disclose
Juliette Hukin
No relationship to disclose
David D. Eisenstat
Honoraria: Roche Canada
Travel, Accommodations, Expenses: Roche Canada
Dorcas Fulton
Consulting or Advisory Role: Merck
Travel, Accommodations, Expenses: Merck
Frank K.H. van Landeghem
No relationship to disclose
Mariarita Santi
No relationship to disclose
Marie-Lise C. van Veelen
No relationship to disclose
Erwin G. Van Meir
No relationship to disclose
Satoru Osuka
No relationship to disclose
Xing Fan
No relationship to disclose
Karin M. Muraszko
No relationship to disclose
Daniela P.C. Tirapelli
No relationship to disclose
Sueli M. Oba-Shinjo
No relationship to disclose
Suely K.N. Marie
No relationship to disclose
Carlos G. Carlotti
No relationship to disclose
Ji Yeoun Lee
No relationship to disclose
Amulya A. Nageswara Rao
No relationship to disclose
Caterina Giannini
No relationship to disclose
Claudia C. Faria
No relationship to disclose
Sofia Nunes
No relationship to disclose
Jaume Mora
No relationship to disclose
Ronald L. Hamilton
No relationship to disclose
Peter Hauser
No relationship to disclose
Nada Jabado
No relationship to disclose
Kevin Petrecca
No relationship to disclose
Shin Jung
No relationship to disclose
© 2016 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Treatment of Posterior Fossa Ependymoma Subgroups
Downloaded from ascopubs.org by 69.119.185.214 on January 3, 2017 from 069.119.185.214
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
Luca Massimi
No relationship to disclose
Massimo Zollo
No relationship to disclose
Giuseppe Cinalli
No relationship to disclose
La´szlo´ Bogna´r
No relationship to disclose
Almos Klekner
No relationship to disclose
Tibor Hortoba´gyi
Stock or Other Ownership: Hortobagyi Med
Research Funding: National Brain Research Program, Hungary
Sarah Leary
No relationship to disclose
Ralph P. Ermoian
Stock or Other Ownership: Several stocks as part of diversified fund:
Abbott Laboratories, Abbvie, Agilent Technologies, Allergan, Becton,
Dickinson and Company, Boston Scientific Corporation, Biogen Idec,
Bristol-Myers Squibb, C. R. Bard, Dyax, Gilead Sciences, Haemonetics
Corporation, Hospira, Illumina, McKesson Corporation, Mylan, Myrexis,
Novartis AG Shareholder, Novo Nordisk AS, Pfizer, Quest Diagnostics,
Quintiles Transnational Holdings, Regeneron Pharmaceuticals, F.
Hoffmann-La Roche, St Jude Medical, SanofiGroup, UnitedHealth Group,
Vertex Pharmaceuticals, Zimmer Holdings, Zoetis
James M. Olson
Leadership: Blaze Bioscience, Presage Biosciences
Stock or Other Ownership: Blaze Bioscience, Presage Biosciences
Research Funding: Takeda
Patents, Royalties, Other Intellectual Property: Inventor on multiple
patents for technologies licensed by Presage Biosciences and Blaze
Bioscience. Receive a fraction of the milestone or royalty payments paid to
Fred Hutchinson Cancer Research Center by these two companies.
Travel, Accommodations, Expenses: Blaze Bioscience, Presage
Biosciences
Jeffrey R. Leonard
No relationship to disclose
Corrine Gardner
No relationship to disclose
Wieslawa A. Grajkowska
No relationship to disclose
Lola B. Chambless
Stock or Other Ownership: Pathfinder Therapeutics (I)
Jason Cain
No relationship to disclose
Charles G. Eberhart
No relationship to disclose
Sama Ahsan
Travel, Accommodations, Expenses: Merck, Merck (I)
Maura Massimino
Consulting or Advisory Role: Genentech, Oncoscience
Felice Giangaspero
No relationship to disclose
Francesca R. Buttarelli
No relationship to disclose
Roger J. Packer
Consulting or Advisory Role: Roche
Lyndsey Emery
No relationship to disclose
William H. Yong
Consulting or Advisory Role: Amgen
Research Funding: Amgen
Horacio Soto
No relationship to disclose
Linda M. Liau
Research Funding: Northwest Biotherapeutics
Richard Everson
No relationship to disclose
Andrew Grossbach
Patents, Royalties, Other Intellectual Property: Medtronic
Tarek Shalaby
No relationship to disclose
Michael Grotzer
No relationship to disclose
Matthias A. Karajannis
Consulting or Advisory Role: MedaCorp
Research Funding: Pfizer (Inst), Novartis (Inst)
David Zagzag
No relationship to disclose
Helen Wheeler
No relationship to disclose
Katja von Hoff
No relationship to disclose
Marta M. Alonso
No relationship to disclose
Teresa Tuñon
No relationship to disclose
Ulrich Schu¨ller
No relationship to disclose
Karel Zitterbart
No relationship to disclose
Jaroslav Sterba
No relationship to disclose
Jennifer A. Chan
No relationship to disclose
Miguel Guzman
No relationship to disclose
Samer K. Elbabaa
Stock or Other Ownership: Pfizer
Howard Colman
Consulting or Advisory Role: Genentech, Upsher-Smith, Roche,
Novocure, Oxigene, CytRx Corporation, Omniox
Research Funding: Newlink Genetics, Plexxikon
Girish Dhall
No relationship to disclose
Paul G. Fisher
Stock or Other Ownership: Johnson & Johnson
www.jco.org © 2016 by American Society of Clinical Oncology
Ramaswamy et al
Downloaded from ascopubs.org by 69.119.185.214 on January 3, 2017 from 069.119.185.214
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
Other Relationship: Associate Editor, The Journal of Pediatrics
Maryam Fouladi
Research Funding: Merck
Amar Gajjar
Research Funding: Genentech (Inst)
Stewart Goldman
No relationship to disclose
Eugene Hwang
Research Funding: Merck Sharp & Dohme
Marcel Kool
No relationship to disclose
Harshad Ladha
No relationship to disclose
Elizabeth Vera-Bolanos
Employment: Horizon Health
Khalida Wani
No relationship to disclose
Frank Lieberman
Consulting or Advisory Role: Optune, Genentech, Stemline Therapeutics
Research Funding: Optune, Stemline Therapeutics, Genentech
Travel, Accommodations, Expenses: Optune
Tom Mikkelsen
Honoraria: Genentech
Consulting or Advisory Role: Genentech, Orbus Therapeutics
Travel, Accommodations, Expenses: Genentech
Antonio M. Omuro
Consulting or Advisory Role: Stemline Therapeutics, Juno Therapeutics,
Bristol-Myers Squibb, Oxigene
Travel, Accommodations, Expenses: Juno Therapeutics, Bristol-Myers
Squibb
Ian F. Pollack
No relationship to disclose
Michael Prados
Honoraria: Actelion
Consulting or Advisory Role: Actelion
Research Funding: Genentech (Inst), Novartis (Inst), Nativis (Inst)
H. Ian Robins
No relationship to disclose
Riccardo Soffietti
Consulting or Advisory Role: Genentech, Celldex
Jing Wu
No relationship to disclose
Phillipe Metellus
No relationship to disclose
Uri Tabori
No relationship to disclose
Ute Bartels
No relationship to disclose
Eric Bouffet
Research Funding: Genentech
Cynthia E. Hawkins
No relationship to disclose
James T. Rutka
No relationship to disclose
Peter Dirks
No relationship to disclose
Stefan M. Pfister
No relationship to disclose
Thomas E. Merchant
Travel, Accommodations, Expenses: IBA
Mark R. Gilbert
Honoraria: Merck, Genentech, Abbvie, Cell Medica, Heron, Wellcome
Trust
Consulting or Advisory Role: Merck/Schering Plough, Genentech,
Abbvie, Heron, Cell Medica, Wellcome Trust
Research Funding: GlaxoSmithKline, Merck/Schering Plough, Genentech
Travel, Accommodations, Expenses:Merck/Schering Plough, Genentech,
Abbvie
Terri S. Armstrong
Consulting or Advisory Role: Tocagen, ImmunoCellular Therapeutics,
Abbvie
Research Funding: Merck/Schering Plough
Andrey Korshunov
No relationship to disclose
David W. Ellison
No relationship to disclose
Michael D. Taylor
No relationship to disclose
© 2016 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Treatment of Posterior Fossa Ependymoma Subgroups
Downloaded from ascopubs.org by 69.119.185.214 on January 3, 2017 from 069.119.185.214
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
Acknowledgment
We thank Narra S. Devi for administrative assistance and Susan Archer for technical writing.
Appendix
Methods
Patient Cohort
All frozen samples were snap frozen and stored at280°C. Both frozen and formalin-fixed paraffin-embedded (FFPE) samples
were collected from diagnosis and, in four instances, from relapse. Criteria for inclusion were an institutional histologic diagnosis of
grade 2 or greater ependymoma and location within the posterior fossa. FFPE tissue was collected as scrolls or unstained slides. The
Global Ependymoma Network of Excellence cohort was deemed the discovery cohort. Samples from three additional cohorts were
collected and processed in an identical manner, including central pathologic review by a single pathologist in each of the three
cohorts. Patients from the three additional cohorts have been partially reported in other cohort studies.12,23,24 Subtotal resection
was defined as greater than 5 mm of postoperative residual disease in at least two planes on postoperative magnetic resonance
imaging or postoperative contrast-enhanced computed tomography scan as per the guidelines of the Children’s Oncology Group
based on institutional radiologic reports. A gross total resection was defined as less than 5 mm of postoperative residual disease on
postoperative magnetic resonance imaging or postoperative contrast-enhanced computed tomography based on institutional
radiologic reports. Assessment of clinical variables pertaining to treatment and survival were performed at local institutions blinded
to the molecular subgrouping. Grading was not included as a variable as a result of previous reports showing the extreme in-
terobserver variability of this measure.24
DNA Extraction
Fresh-frozen posterior fossa ependymomas were stored at280°C before processing for extraction of DNA. For frozen samples,
DNA extraction was performed using a proteinase K digestion and phenol:chloroform:isoamyl alcohol extraction and ethanol
precipitation.25 FFPE samples were processed using the Qiagen DNeasy FFPE extraction kit (Qiagen, Hilden, Germany), as per the
manufacturer’s instructions.26 Samples were quantified using Picogreen (Life Technologies, Waltham, MA).
Genome-Wide DNA Methylation Profiling
All samples were analyzed on the Illumina Infinium HumanMethylation450 BeadChip (Illumina, San Diego, CA) at the
Princess Margaret Genomics Centre (Toronto, Ontario, Canada), the St Jude Children’s Research Hospital (Memphis, TN), or the
German Cancer Research Center (Heidelberg, Germany) according to the manufacturer’s instructions and as previously described.
All analysis was conducted in the R Statistical Environment (v3.1.3; www.r-project.org). Raw data files (.idat) were processed as
previously described, and ependymoma subgroup affiliation was assigned as per a recently released classifier using unsupervised
hierarchical clustering.23 Thirty-five grade 1 ependymomas (myxopapillary and subependymomas) were excluded from the
analysis based on this classifier. Eleven samples diagnosed as ependymomas by local institutions did not cluster with posterior fossa
ependymoma and were removed from the analysis.
Statistical Analysis
Progression-free survival and overall survival were right censored at 10 years and analyzed using the Kaplan-Meier method, and
P values were determined using the log-rank test. Administrative censoring at 10 years was performed to ensure a reasonable
completeness of follow-up across all four cohorts as a result of declining patient numbers at longer follow-up times. Administrative
censoring resulted in only 1.6% of additionally censored patients at the end of the follow-up period for overall survival. As such,
both continuous and censored data are presented. Survival data are presented as survival estimates including 95% CIs. A pro-
gression event was defined as the earliest time point between two assessment times with clear radiologic progression as reported by
the local institution, and progression-free survival was defined as the interval between the initial diagnosis (typically surgery) and
the progression event. Overall survival was calculated as the time from surgery to the time of death from any cause as reported by the
referring institution. Associations between covariates and risk groups were tested using the Fisher’s exact test. Univariable and
multivariable Cox proportional hazards regression was used to estimate hazard ratios including 95% CIs. In pooled analysis, cohort
was included as a stratification variable in the Cox model. In some EPN_PFB subgroup analysis, Firth correction was applied as
a result of monotone likelihoods.27 Age-dependent relative hazards for PFA/PFB subgroups were estimated from a Cox model with
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age and subgroup interaction and a restricted cubic spline function with three knots for age to allow for a nonlinear relationship. All
P values reported are two-sided. All statistical analyses were performed in the R statistical environment (v3.1.2), using R packages of
survival (v2.37-7), rms (4.3-1), Coxphf (v1.1), and ggplot2 (v1.0.0).
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Fig A1. (A-D) Boxplots of the age distribution of EPN_PFA and EPN_PFB, where boxes represent median and interquartile range and whiskers represent 95% CIs. (E)
Proportion of patients with EPN_PFA and EPN_PFB in each age group. CERN, Collaborative Ependymoma Research Network; GENE, Global Ependymoma Network of
Excellence.
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multivariable analysis for (A) progression-free survival (PFS) and (B) overall survival (OS). CERN, Collaborative Ependymoma Research Network; GENE, Global Epen-
dymoma Network of Excellence.
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Fig A3. Plot of age at diagnosis as a function of the log10 of the hazard ratios of EPN_PFA versus EPN_PFB for (A) progression-free survival (PFS) and (B) overall survival
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Fig A4. Survival by subgroup in patients with an age at diagnosis of greater than 10 years for (A) progression-free survival (PFS) and (B) overall survival (OS).
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Fig A6. Overall survival (OS) of EPN_PFA for the four cohorts divided by (A, C, and E) gross total resection (GTR) and (B, D, and F) subtotal resection (STR). P values were
determined using the log-rank test. CERN, Collaborative Ependymoma Research Network; GENE, Global Ependymoma Network of Excellence; XRT, radiotherapy.
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Fig A7. Progression-free survival (PFS) and overall survival (OS) EPN_PFB stratified by extent of resection for (A and B) the combined Global Ependymoma Network of
Excellence (GENE), St Jude’s, and Collaborative Ependymoma Research Network (CERN) cohorts and (C and D) the Burdenko Cohort. GTR, gross total resection; STR,
subtotal resection.
© 2016 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Treatment of Posterior Fossa Ependymoma Subgroups
Downloaded from ascopubs.org by 69.119.185.214 on January 3, 2017 from 069.119.185.214
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
Table A1. Multivariable Cox Proportional Hazards Model of Survival Across All Posterior Fossa Ependymomas
Variable
PFS OS
HR (95% CI) P HR (95% CI) P
GENE cohort (PFS, n = 304; OS, n = 305)
Subgroup EPN_PFA 2.66 (1.14 to 6.23) .02 6.11 (1.38 to 27.01) .02
Age 0.97 (0.95 to 0.99) .008 0.96 (0.93 to 0.99) .02
Incomplete resection 1.87 (1.31 to 2.67) , .001 2.37 (1.55 to 3.64) , .001
Adjuvant first-line radiation 0.30 (0.21 to 0.44) , .001 0.29 (0.18 to 0.45) , .001
Adjuvant first-line chemotherapy 1.07 (0.74 to 1.55) .72 0.75 (0.47 to 1.20) .23
Male 1.19 (0.86 to 1.66) .30 1.26 (0.83 to 1.89) .28
CERN cohort (PFS, n = 120; OS, n = 120)
Subgroup EPN_PFA 2.08 (0.65 to 6.66) .22 6.95 (1.13 to 42.71) .04
Age 1.00 (0.97 to 1.03) .89 1.01 (0.97 to 1.05) .73
Incomplete resection 1.59 (0.91 to 2.79) .10 1.79 (0.87 to 3.70) .12
Adjuvant first-line radiation 0.70 (0.43 to 1.14) .15 0.62 (0.33 to 1.17) .14
Adjuvant first-line chemotherapy 0.95 (0.51 to 1.79) .88 0.79 (0.37 to 1.72) .56
Male 1.17 (0.73 to 1.90) .51 2.12 (1.07 to 4.21) .03
St Jude RT1 cohort (PFS, n = 112; OS, n = 112)
Subgroup EPN_PFA 1.40 (0.25 to 7.96) .70 4.94 (0.43 to 698.63) .23
Age 0.99 (0.89 to 1.10) .87 1.05 (0.91 to 1.17) .51
Incomplete resection 2.75 (1.42 to 5.33) .003 3.27 (1.47 to 6.90) .005
Male 2.16 (1.15 to 4.06) .009 2.72 (1.23 to 6.74) .01
Burdenko cohort (PFS, n = 241; OS, n = 241)
Subgroup EPN_PFA 2.49 (0.98 to 6.35) .06 2.72 (0.51 to 14.67) .24
Age 0.99 (0.96 to 1.02) .61 0.98 (0.93 to 1.04) .49
Incomplete resection 2.03 (1.43 to 2.89) , .001 2.00 (1.19 to 3.37) .009
Adjuvant first-line radiation 1.11 (0.74 to 1.66) .61 1.08 (0.60 to 1.95) .80
Adjuvant first-line chemotherapy 0.99 (0.65 to 1.49) .94 1.38 (0.71 to 2.66) .34
Male 1.10 (0.76 to 1.58) .62 0.85 (0.50 to 1.45) .55
Abbreviations: CERN, Collaborative Ependymoma Research Network; GENE, Global Ependymoma Network of Excellence; HR, hazard ratio; OS, overall survival; PFS,
progression-free survival.
Table A2. Multivariable Cox Proportional Hazards RegressionModel of 10-Year
Progression-Free and Overall Survival
Variable Hazard Ratio 95% CI P
Progression-free survival (n = 777)
Age 0.99 0.97 to 1.00 .09
Male 1.25 1.01 to 1.54 .04
Incomplete resection 1.88 1.51 to 2.33 , .001
Adjuvant first-line radiation 0.63 0.50 to 0.81 , .001
Adjuvant first-line chemotherapy 1.02 0.79 to 1.32 .87
EPN_PFA subgroup 2.18 1.31 to 3.62 .003
Overall survival (n = 778)
Age 0.98 0.96 to 1.00 .13
Male 1.40 1.06 to 1.84 .02
Incomplete resection 2.14 1.61 to 2.84 , .001
Adjuvant first-line radiation 0.52 0.38 to 0.71 , .001
Adjuvant first-line chemotherapy 0.91 0.66 to 1.27 .6
EPN_PFA Subgroup 4.27 1.86 to 9.81 , .001
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Table A3. Multivariable Cox Proportional Hazards Model of 10-Year Survival Across All Posterior Fossa Ependymoma
Variable
PFS OS
HR (95% CI) P HR (95% CI) P
GENE cohort (PFS, n = 304; OS, n =3 05)
Subgroup EPN_PFA 2.61 (1.04 to 6.53) .04 5.26 (1.17 to 23.60) .03
Age 0.96 (0.93 to 0.99) .005 0.96 (0.92 to 1.00) .03
Incomplete resection 1.90 (1.33 to 2.72) , .001 2.49 (1.61 to 3.87) , .001
Adjuvant first-line radiation 0.29 (0.20 to 0.43) , .001 0.27 (0.17 to 0.43) , .001
Adjuvant first-line chemotherapy 1.01 (0.69 to 1.47) .96 0.75 (0.47 to 1.22) .25
Male 1.16 (0.83 to 1.61) .40 1.20 (0.79 to 1.82) .40
CERN cohort (PFS, n = 120; OS, n = 120)
Subgroup EPN_PFA 2.08 (0.65 to 6.66) .22 7.52 (1.09 to 51.67) .04
Age 1.00 (0.97 to 1.03) .89 1.00 (0.96 to 1.05) .73
Incomplete resection 1.59 (0.91 to 2.79) .10 1.82 (0.86 to 3.85) .12
Adjuvant first-line radiation 0.70 (0.43 to 1.14) .15 0.67 (0.53 to 1.28) .22
Adjuvant first-line chemotherapy 0.95 (0.51 to 1.79) .88 0.77 (0.35 to 1.68) .51
Male 1.17 (0.73 to 1.90) .51 2.02 (1.01 to 4.04) .05
St Jude RT1 cohort (PFS, n = 112; OS, n = 112)
Subgroup EPN_PFA 2.87 (0.31 to 26.73) .35 4.68 (0.40 to 662.59) .25
Age 1.00 (0.90 to 1.11) 1.00 1.05 (0.91 to 1.18) .47
Incomplete resection 2.77 (1.42 to 5.38) .003 3.49 (1.56 to 7.45) .003
Male 2.42 (1.25 to 4.67) .009 3.16 (1.38 to 8.30) .006
Burdenko cohort (PFS, n = 241; OS, n = 241)
Subgroup EPN_PFA 2.46 (0.97 to 6.24) .06 2.90 (0.54 to 15.55) .21
Age 0.99 (0.96 to 1.02) .63 0.98 (0.93 to 1.04) .52
Incomplete resection 2.00 (1.40 to 2.84) , .001 2.01 (1.18 to 3.42) .01
Adjuvant first-line radiation 1.09 (0.73 to 1.64) .66 1.10 (0.60 to 2.03) .75
Adjuvant first-line chemotherapy 1.01 (0.66 to 1.54) .96 1.31 (0.67 to 2.54) .43
Male 1.10 (0.76 to 1.58) .62 0.84 (0.49 to 1.42) .51
Abbreviations: CERN, Collaborative Ependymoma Research Network; GENE, Global Ependymoma Network of Excellence; HR, hazard ratio; OS, overall survival; PFS,
progression-free survival.
Table A4. Predictor-Cohort Interaction Likelihood Ratio Test for Both Progression-Free Survival and Overall Survival
Predictor
P
PFS OS
EPN subgroup .35 .84
Age .09 .68
Extent of resection .79 .49
Sex .37 .14
Adjuvant first-line chemotherapy .70 .82
Adjuvant first-line radiation , .001 .009
NOTE. Values represent the P values for a likelihood ratio test for predictor-cohort interaction.
Abbreviations: OS, overall survival; PFS, progression-free survival.
Table A5. The 5- and 10-Year Survival of Patients With EPN_PFA and EPN_PFB Older Than Age 10 Years
Survival EPN_PFA EPN_PFB
No. of patients 54 128
Median PFS (95% CI)
5-year PFS 0.537 (0.413 to 0.698) 0.828 (0.761 to 0.900)
10-year PFS 0.412 (0.283 to 0.600) 0.622 (0.513 to 0.756)
Median OS (95% CI)
5-year OS 0.705 (0.585 to 0.849) 0.981 (0.955 to 1.000)
10-year OS 0.598 (0.458 to 0.780) 0.868 (0.771 to 0.977)
Abbreviations: OS, overall survival; PFS, progression-free survival.
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Table A6. The 5- and 10-Year Survival of Patients With EPN_PFA Stratified by GTR and STR Across Four Cohorts
Survival
Median (95% CI)
GENE St Jude’s CERN Burdenko
GTR
5-year PFS 0.467 (0.386 to 0.544) 0.707 (0.596 to 0.793) 0.667 (0.515 to 0.781) 0.453 (0.354 to 0.547)
5-year OS 0.688 (0.605 to 0.756) 0.879 (0.786 to 0.933) 0.739 (0.587 to 0.843) 0.781 (0.682 to 0.853)
10-year PFS 0.425 (0.339 to 0.508) 0.676 (0.561 to 0.767) 0.459 (0.299 to 0.606) 0.369 (0.261 to 0.476)
10-year OS 0.628 (0.533 to 0.710) 0.774 (0.660 to 0.854) 0.567 (0.389 to 0.711) 0.661 (0.526 to 0.766)
STR
5-year PFS 0.370 (0.261 to 0.479) 0.526 (0.287 to 0.719) 0.568 (0.394 to 0.708) 0.261 (0.175 to 0.356)
5-year OS 0.535 (0.413 to 0.643) 0.590 (0.345 to 0.770) 0.681 (0.499 to 0.809) 0.658 (0.540 to 0.753)
10-year PFS 0.259 (0.141 to 0.394) 0.301 (0.102 to 0.531) 0.218 (0.100 to 0.365) 0.143 (0.067 to 0.247)
10-year OS 0.327 (0.194 to 0.467) 0.451 (0.214 to 0.663) 0.401 (0.221 to 0.575) 0.433 (0.280 to 0.577)
Abbreviations: CERN, Collaborative Ependymoma Research Network; GENE, Global Ependymoma Network of Excellence; GTR, gross total resection; OS, overall
survival; PFS, progression-free survival; STR, subtotal resection.
Table A7. Multivariable Cox Proportional Hazards Model of Survival in EPN_PFA
Variable
PFS OS
HR (95% CI) P HR (95% CI) P
All cohorts (PFS, n = 645; OS, n = 646)
Age 0.98 (0.96 to 1.00) .08 0.99 (0.96 to 1.01) .26
Incomplete resection 1.71 (1.37 to 2.14) , .001 2.05 (1.52 to 2.76) , .001
Adjuvant radiation 0.64 (0.50 to 0.82) , .001 0.52 (0.38 to 0.72) , .001
Adjuvant chemotherapy 1.04 (0.81 to 1.35) .74 0.89 (0.63 to 1.26) .51
Male 1.31 (1.05 to 1.62) .02 1.39 (1.04 to 1.85) .02
GENE cohort (PFS, n = 258; OS, n = 259)
Age 0.96 (0.93 to 0.99) .007 0.96 (0.91 to 1.00) .03
Incomplete resection 1.68 (1.17 to 2.42) .005 2.26 (1.46 to 3.49) , .001
Adjuvant radiation 0.31 (0.21 to 0.45) , .001 0.28 (0.18 to 0.45) , .001
Adjuvant chemotherapy 1.08 (0.74 to 1.58) .68 0.78 (0.49 to 1.25) .30
Male 1.10 (0.79 to 1.55) .57 1.17 (0.77 to 1.78) .46
CERN cohort (PFS, n = 86; OS, n = 86)
Age 1.00 (0.96 to 1.04) .92 1.01 (0.97 to 1.06) .53
Incomplete resection 1.63 (0.85 to 3.12) .14 1.80 (0.83 to 3.88) .13
Adjuvant radiation 0.73 (0.43 to 1.25) .25 0.61 (0.31 to 1.18) .14
Adjuvant chemotherapy 0.89 (0.46 to 1.72) .73 0.77 (0.35 to 1.67) .50
Male 1.40 (0.81 to 2.43) .23 2.51 (1.18 to 5.33) .02
St Jude’s RT1 cohort (PFS, n = 104; OS, n = 104)
Age 1.00 (0.90 to 1.12) .94 1.04 (0.91 to 1.19) .61
Incomplete resection 2.71 (0.40 to 5.26) .003 3.26 (1.49 to 7.12) .003
Male 2.42 (1.25 to 4.69) .009 2.86 (1.21 to 6.77) .02
Burdenko cohort (PFS, n = 197; OS, n = 197)
Age 0.99 (0.96 to 1.03) .77 1.01 (0.96 to 1.06) .70
Incomplete resection 1.88 (1.30 to 2.71) , .001 1.84 (1.08 to 3.12) .02
Adjuvant radiation 1.12 (0.74 to 1.70) .60 1.02 (0.56 to 1.85) .94
Adjuvant chemotherapy 0.98 (0.64 to 1.49) .92 1.42 (0.73 to 2.78) .30
Male 1.19 (0.81 to 1.77) .38 0.89 (0.51 to 1.53) .66
Abbreviations: CERN, Collaborative Ependymoma Research Network; GENE, Global Ependymoma Network of Excellence; HR, hazard ratio; OS, overall survival; PFS,
progression-free survival.
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Table A8. Multivariable Cox Proportional Hazards Model of 10-Year Survival in EPN_PFA
Variable
PFS OS
HR (95% CI) P HR (95% CI) P
All cohorts (PFS, n = 645; OS, n = 646)
Age 0.98 (0.96 to 1.00) .07 0.99 (0.96 to 1.01) .26
Incomplete resection 1.74 (1.39 to 2.18) , .001 2.05 (1.52 to 2.76) , .001
Adjuvant radiation 0.65 (0.50 to 0.83) , .001 0.52 (0.38 to 0.72) , .001
Adjuvant chemotherapy 1.03 (0.80 to 1.34) .80 0.89 (0.63 to 1.26) .51
Male 1.31 (1.05 to 1.63) .02 1.39 (1.04 to 1.85) .02
GENE cohort (PFS, n = 258; OS, n = 259)
Age 0.95 (0.92 to 0.99) .008 0.96 (0.91 to 1) .03
Incomplete resection 1.74 (1.21 to 2.52) .003 2.26 (1.46 to 3.49) , .001
Adjuvant radiation 0.31 (0.21 to 0.45) , .001 0.28 (0.18 to 0.45) , .001
Adjuvant chemotherapy 1.03 (0.70 to 1.51) .88 0.78 (0.49 to 1.25) .30
Male 1.09 (0.78 to 1.53) .62 1.17 (0.77 to 1.78) .46
CERN cohort (PFS, n = 86; OS, n = 86)
Age 1.00 (0.96 to 1.40) .92 1.01 (0.97 to 1.06) .53
Incomplete resection 1.91 (0.98 to 3.75) .06 1.80 (0.83 to 3.88) .13
Adjuvant radiation 0.84 (0.47 to 1.48) .54 0.61 (0.31 to 1.18) .14
Adjuvant chemotherapy 0.82 (0.42 to 1.61) .57 0.77 (0.35 to 1.67) .50
Male 1.46 (0.82 to 2.59) .20 2.51 (1.18 to 5.33) .02
St Jude’s RT1 Cohort (PFS, n = 104; OS, n = 104)
Age 1.01 (0.90 to 1.12) .9 1.04 (0.91 to 1.19) .61
Incomplete resection 2.77 (1.43 to 5.38) .003 3.26 (1.49 to 7.12) .003
Male 2.59 (1.31 to 5.10) .006 2.86 (1.21 to 6.77) .02
Burdenko cohort (PFS, n = 197; OS, n = 197)
Age 0.99 (0.96 to 1.03) .80 1.01 (0.96 to 1.06) .70
Incomplete resection 1.84 (1.28 to 2.66) .001 1.84 (1.08 to 3.12) .02
Adjuvant radiation 1.10 (0.72 to 1.67) .66 1.02 (0.56 to 1.85) .94
Adjuvant chemotherapy 1.00 (0.65 to 1.54) .99 1.42 (0.73 to 2.78) .30
Male 1.19 (0.81 to 1.77) .38 0.89 (0.51 to 1.53) .66
Abbreviations: CERN, Collaborative Ependymoma Research Network; GENE, Global Ependymoma Network of Excellence; HR, hazard ratio; OS, overall survival; PFS,
progression-free survival.
Table A9. Multivariable Cox Proportional Hazards Model of Survival in EPN_PFB in All Cohorts
Variable
Progression-Free Survival (n = 132) Overall Survival (n = 132)
HR (95% CI) P HR (95% CI) P
Age 0.99 (0.97 to 1.02) .70 0.98 (0.92 to 1.04) .45
Incomplete resection 3.93 (1.78 to 8.68) , .001 11.32 (1.28 to 100.41) .03
Adjuvant radiation 0.49 (0.21 to 1.14) .10 0.53 (0.09 to 3.06) .48
Adjuvant chemotherapy 1.64 (0.45 to 5.92) .45 5.37 (0.45 to 64.12) .18
Male 0.76 (0.37 to 1.59) .47 0.76 (0.15 to 3.79) .74
Abbreviation: HR, hazard ratio.
Table A10. Multivariable Cox Proportional Hazards Model of 10-Year Survival in EPN_PFB in All Cohorts
Variable
Progression Free Survival (n = 132) Overall Survival (n = 132)
HR (95% CI) P HR (95% CI) P
Age 0.99 (0.96 to 1.02) .52 0.97 (0.91 to 1.04) .38
Incomplete resection 4.30 (1.89 to 9.77) , .001 11.06 (1.24 to 98.32) .03
Adjuvant radiation 0.49 (0.21 to 1.16) .10 0.51 (0.09 to 2.99) .45
Adjuvant chemotherapy 1.51 (0.42 to 5.41) .45 4.93 (0.42 to 58.18) .20
Male 0.69 (0.32 to 1.47) .33 0.77 (0.15 to 3.84) .75
Abbreviation: HR, hazard ratio.
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